GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Omeros Corp (LTS:0KBU) » Definitions » Loans Receivable

Omeros (LTS:0KBU) Loans Receivable : $0.00 Mil (As of Sep. 2024)


View and export this data going back to 2018. Start your Free Trial

What is Omeros Loans Receivable?

Omeros's Loans Receivable for the quarter that ended in Sep. 2024 was $0.00 Mil.


Omeros Loans Receivable Historical Data

The historical data trend for Omeros's Loans Receivable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Omeros Loans Receivable Chart

Omeros Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Loans Receivable
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Omeros Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Loans Receivable Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Omeros Loans Receivable Calculation

Loans Receivable are the funds that a company has lent but have not yet been repaid.


Omeros Loans Receivable Related Terms

Thank you for viewing the detailed overview of Omeros's Loans Receivable provided by GuruFocus.com. Please click on the following links to see related term pages.


Omeros Business Description

Traded in Other Exchanges
Address
201 Elliott Avenue West, Seattle, WA, USA, 98119
Omeros Corp is a United States-based clinical-stage biopharmaceutical company engaged in discovering, developing, and commercializing small-molecule and protein therapeutics for large-market as well as orphan indications targeting immunologic disorders including complement-mediated diseases, cancers, and addictive and compulsive disorders. The lead drug candidate in the pipeline of complement-targeted therapeutics is narsoplimab (OMS721), a proprietary, patented human monoclonal antibody targeting mannan-binding lectin-associated serine protease 2, the key activator of the lectin pathway of complement. Clinical development of narsoplimab is currently focused on hematopoietic stem cell transplant-associated thrombotic microangiopathy and immunoglobulin nephropathy.

Omeros Headlines

No Headlines